A monoclonal antibody that targets the PD-L1 protein. Attegizumab binds to PD-L1 expressed on tumor cells and tumor infiltrating immune cells, blocking its interaction with PD-1 and B7.1 receptors. By inhibiting PD-L1, it can activate T-cells to destroy tumor cells. This evidence concerns the gene CD274 and neoplasm.